IN DELIVERED NANOMEDICINE CROSSING THE BBB CONTINUOUSLY MAKES HIGHLY ACTIVE BCHE.

$5,083,968FY2014Defense Threat Reduction AgencyDOD

Synergene Therapeutics Inc

Investigators